From Name:
From Email:
To Name:
To Email:

Optional Message:


FDA Warns of Increased Major Adverse Cardiac Events With the Absorb Dissolving Stent

from Cardiovascular Business

After reviewing data from a clinical trial, the U.S. Food and Drug Administration (FDA) issued a letter to healthcare providers informing them that patients who received the Absorb bioresorbable vascular scaffold had an increased rate of major adverse cardiac events compared with patients treated with the Xience drug-eluting stent. The FDA issued the safety alert March 18. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063